Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.
- Fritzen K Sciarc GmbH, Baierbrunn, Germany.
- Basinska K Sciarc GmbH, Baierbrunn, Germany.
- Rubio-Almanza M Endocrinology and Nutrition Department Hospital Universitario y Politécnico La Fe and Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
- Nicolucci A Center for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy.
- Kennon B FRCP, Diabetes Centre, Queen Elizabeth University Hospital, Glasgow, UK.
- Vergès B Endocrinologie, Diabétologie, Maladies Métaboliques et Nutrition, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.
- Zakrzewska K LifeScan Europe GmbH, Zug, Switzerland.
- Schnell O Sciarc GmbH, Baierbrunn, Germany.
- 2019-03-29
Published in:
- Journal of diabetes science and technology. - 2019
blood glucose self-monitoring
cost-effectiveness analysis
diabetes mellitus
telemedicine
Blood Glucose
Blood Glucose Self-Monitoring
Cost Savings
Cost-Benefit Analysis
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Europe
Humans
Hypoglycemic Agents
Insulin
Telemedicine
English
BACKGROUND
Self-monitoring of blood glucose supported by the diabetes-app OneTouch Reveal® has demonstrated to improve HbA1c. We aimed at analyzing costs savings related the integration of telemedical features into diabetes management.
METHODS
Data from a randomized controlled trial were used to assess the 10-year risk of patients for fatal myocardial infarction (MI). On the basis of this risk assessments-also related to a 5% or 10% reduction of hypoglycemic episodes-cost savings for the health care systems of five European countries-France, Germany, Italy, Spain, and the United Kingdom-were modeled.
RESULTS
HbA1c reduction of 0.92% in insulin-treated type 2 diabetes patients (T2DM) was associated with a 2.3% decreased 10-year risk for fatal MI. In combination with a 10% reduction of hypoglycemic events this risk reduction led to cost savings of €16.1 million (France), €57.8 million (Germany), €30.9 million (Italy), €23.8 million (Spain), and €5.8 million (UK), considering all insulin-treated T2DM patients in the respective countries.
CONCLUSION
Improving metabolic control and thus risk for comorbidities like MI by combining the glucose meter with CRI with telemedical features has the potential to reduce costs for European health care systems.
Self-monitoring of blood glucose supported by the diabetes-app OneTouch Reveal® has demonstrated to improve HbA1c. We aimed at analyzing costs savings related the integration of telemedical features into diabetes management.
METHODS
Data from a randomized controlled trial were used to assess the 10-year risk of patients for fatal myocardial infarction (MI). On the basis of this risk assessments-also related to a 5% or 10% reduction of hypoglycemic episodes-cost savings for the health care systems of five European countries-France, Germany, Italy, Spain, and the United Kingdom-were modeled.
RESULTS
HbA1c reduction of 0.92% in insulin-treated type 2 diabetes patients (T2DM) was associated with a 2.3% decreased 10-year risk for fatal MI. In combination with a 10% reduction of hypoglycemic events this risk reduction led to cost savings of €16.1 million (France), €57.8 million (Germany), €30.9 million (Italy), €23.8 million (Spain), and €5.8 million (UK), considering all insulin-treated T2DM patients in the respective countries.
CONCLUSION
Improving metabolic control and thus risk for comorbidities like MI by combining the glucose meter with CRI with telemedical features has the potential to reduce costs for European health care systems.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1177/1932296819835172
- PMID 30917691
- Persistent URL
- https://sonar.ch/global/documents/238183
Statistics
Document views: 17
File downloads:
- Full-text: 0